​

Veracyte (VCYT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VCYT Stock Forecast

Veracyte (VCYT) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $57.43, with a high of $69.00 and a low of $44.00. This represents a 30.94% increase from the last price of $43.86.

$15 $26 $37 $48 $59 $70 High: $69 Avg: $57.43 Low: $44 Last Closed Price: $43.86

VCYT Stock Rating

Veracyte stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (66.67%), 6 Hold (28.57%), 1 Sell (4.76%), and 0 Strong Sell (0.00%).

Buy
Total 21 1 6 14 0 Strong Sell Sell Hold Buy Strong Buy

VCYT Price Target Upside V Benchmarks

TypeNameUpside
StockVeracyte30.94%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks7.81%

Price Target Trends

1M3M12M
# Anlaysts11019
Avg Price Target$65.00$57.50$52.21
Last Closing Price$43.86$43.86$43.86
Upside/Downside48.20%31.10%19.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 262811-12
Aug, 262811-12
Jul, 261811-11
Jun, 261811-11
May, 261911-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026UBS$65.00$42.4553.12%48.20%
Aug 04, 2026Morgan Stanley$44.00$44.49-1.10%0.32%
Aug 04, 2026Stephens$55.00$44.8522.63%25.40%
Aug 04, 2026Piper Sandler$54.00$44.8520.40%23.12%
Aug 03, 2026Kyle MiksonCanaccord Genuity$50.00$46.327.94%14.00%
Jul 31, 2026Mike MatsonNeedham$69.00$59.7815.42%57.32%
Jul 15, 2026David WestenbergPiper Sandler$66.00$56.6216.57%50.48%
Jul 14, 2026Canaccord Genuity$60.00$57.484.38%36.80%
Jul 09, 2026Morgan Stanley$47.00$56.12-16.25%7.16%
Jun 29, 2026Subbu NambiGuggenheim$65.00$60.497.46%48.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2026NeedhamBuyBuyhold
Jul 15, 2026Piper SandlerOverweightinitialise
Jul 09, 2026Morgan StanleyUnderweightUnderweighthold
Jun 29, 2026GuggenheimBuyBuyhold
Jun 01, 2026NeedhamBuyBuyhold
May 06, 2026UBSBuyBuyhold
Mar 05, 2026Morgan StanleyUnderweightUnderweighthold
Jan 12, 2026UBSBuyBuyhold
Jan 05, 2026GuggenheimBuyBuyhold
Nov 05, 2025UBSBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.11$-0.51$-1.02$0.32$0.84----
Avg Forecast$-1.14$-0.61$-0.71$0.36$0.50$0.71$1.12$1.38$1.52
High Forecast$-1.14$-0.61$-0.62$0.37$0.53$0.88$1.59$1.40$1.55
Low Forecast$-1.14$-0.61$-0.77$0.35$0.48$0.54$0.65$1.35$1.49
Surprise %-2.63%-16.39%43.66%-11.11%68.00%----

Revenue Forecast

$200M $300M $400M $500M $600M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$219.51M$296.54M$361.05M$445.76M$517.14M----
Avg Forecast$214.82M$291.31M$354.58M$443.91M$487.76M$540.63M$592.77M$636.08M$672.40M
High Forecast$214.82M$291.31M$354.58M$445.00M$490.33M$556.35M$592.84M$645.88M$682.76M
Low Forecast$214.82M$291.31M$354.58M$442.63M$486.23M$531.04M$592.70M$626.12M$661.88M
Surprise %2.19%1.79%1.82%0.42%6.02%----

Net Income Forecast

$-250M $-170M $-90M $-10M $70M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-75.56M$-36.56M$-74.40M$24.14M$66.35M----
Avg Forecast$-170.25M$-59.07M$-74.40M$28.69M$40.22M$53.25M$73.70M$109.87M$121.46M
High Forecast$-136.20M$-47.26M$-59.52M$29.34M$42.10M$70.49M$126.78M$112.07M$123.89M
Low Forecast$-204.30M$-70.88M$-89.28M$28.03M$38.33M$42.91M$52.20M$107.63M$118.99M
Surprise %-55.62%-38.11%--15.85%64.98%----

VCYT Forecast FAQ

Is Veracyte stock a buy?

Veracyte stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Veracyte is a favorable investment for most analysts.

What is Veracyte's price target?

Veracyte's price target, set by 21 Wall Street analysts, averages $57.43 over the next 12 months. The price target range spans from $44 at the low end to $69 at the high end, suggesting a potential 30.94% change from the previous closing price of $43.86.

How does Veracyte stock forecast compare to its benchmarks?

Veracyte's stock forecast shows a 30.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (7.81%).

What is the breakdown of analyst ratings for Veracyte over the past three months?

  • September 2026: 16.67% Strong Buy, 66.67% Buy, 8.33% Hold, 8.33% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 66.67% Buy, 8.33% Hold, 8.33% Sell, 0% Strong Sell.
  • July 2026: 9.09% Strong Buy, 72.73% Buy, 9.09% Hold, 9.09% Sell, 0% Strong Sell.

What is Veracyte’s EPS forecast?

Veracyte's average annual EPS forecast for its fiscal year ending in December 2026 is $0.71, marking a -15.48% decrease from the reported $0.84 in 2025. Estimates for the following years are $1.12 in 2027, $1.38 in 2028, and $1.52 in 2029.

What is Veracyte’s revenue forecast?

Veracyte's average annual revenue forecast for its fiscal year ending in December 2026 is $540.63M, reflecting a 4.54% increase from the reported $517.14M in 2025. The forecast for 2027 is $592.77M, followed by $636.08M for 2028, and $672.4M for 2029.

What is Veracyte’s net income forecast?

Veracyte's net income forecast for the fiscal year ending in December 2026 stands at $53.25M, representing a -19.75% decrease from the reported $66.35M in 2025. Projections indicate $73.7M in 2027, $109.87M in 2028, and $121.46M in 2029.